undamentalytics Newsletter
Sign in

Dentsply Sirona Inc. (XRAY) stock

Add to watchlist

Add holding +

NASDAQ: XRAY Nasdaq Health Care Supplies Next results ~November 5, 2026

C Fundamentals grade

Dentsply Sirona Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 43% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 43% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Dentsply Sirona Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders9 buying, 1 selling12 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds200 adding, 179 cuttingOf 56 active managers that changed their stake, 26 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Dentsply Sirona files

Where Dentsply Sirona stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $3.64bn, down 0.8% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin held at 3.9%. Operating margin widened to -8.5% from -28.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 7 financial-health checks.

Our model value for Dentsply Sirona is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Dentsply Sirona Inc.'s trailing-twelve-month revenue fell 0.8% year on year, with a free-cash-flow margin of 3.9%. Where it stands out: stock pay as % of revenue of 0.9% ranks 2 of 13 health care supplies companies we cover. Where it lags: long-term debt as % of assets of 38.4% ranks 8 of 9 health care supplies companies we cover.

Our discounted-cash-flow model values the business at ~$8.2 per share in the base case (~$3.3–$15 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 3.6% while net income grew 42.5%: a 39pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 19.7 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 0.8% over the last 12 months.
  • Loss-making. Operating margin is -8.5%: costs exceed revenue.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 1.1 against the S&P 500.
  • Gross margin slipping. Gross margin is down 2.2 points on a year ago.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 38.4% ranks 8 of 9 health care supplies companies we cover (median 15.4%).
  • Heavily shorted. 14.3% of the shares available to trade are sold short (5.4 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
$0.52 against an average estimate of $0.35: beat by 50.1%
Revenue
$898m, down 4.1% on a year earlier
Next report
November 5, 2026; average EPS estimate $0.31

Dentsply Sirona's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.9%
  • 1 week+7.4%
  • 1 month+14.2%
  • This year-13.4%
  • 1 year-20.4%
  • 5 years-81.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.6B
Operating margin
-8.5%
Net margin
-15.0%
EPS (TTM, diluted)
$-2.73

Growth

Revenue growth
−0.8%
Change in growth rate
+0.3 pts
Share count change
+0.1%

Cash

Free cash flow (TTM)
$143M
FCF margin
3.9%
Stock pay % of revenue
0.9%

Earnings

Last results
May 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Dentsply Sirona Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 43% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Dentsply Sirona Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.7%: the 10-year Treasury yield (4.9%) plus a beta of 0.83 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$18 ~$19–$38 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Dentsply Sirona Inc. with Health Care Supplies in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$52.59$50.16$57.51$32.78$50.21$46.90$50.33$29.14$33.07$18.10$11.43$9.90
Market value$7.5bn$11.1bn$13.2bn$7.4bn$11.3bn$10.3bn$11.1bn$6.3bn$7.0bn$3.7bn$2.3bn$2.0bn
+ Net debt (− = net cash)$869m$1.1bn$1.3bn$1.3bn$1.0bn$1.8bn$1.8bn$1.6bn$1.8bn$1.9bn$2.0bn$2.0bn
Enterprise value$8.4bn$12.3bn$14.5bn$8.7bn$12.3bn$12.1bn$12.8bn$7.9bn$8.8bn$5.5bn$4.3bn$4.0bn
Multiples
Price / sales 2.8x3.0x3.3x1.8x2.8x3.1x2.6x1.6x1.8x1.0x0.6x0.5x
Price / earnings 29.8x25.9x——44.0x—27.0x—————
Price / free cash flow 17.6x25.4x28.8x23.2x21.8x18.3x21.5x17.1x30.7x13.1x21.9x13.8x
EV / EBITDA 16.8x16.9x——18.2x36.6x13.4x—34.1x——101.6x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

62 /100

Moderate moat

How hard Dentsply Sirona's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 6 / 20

    Cash operating profit has been a median 5.6% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 52.7%, moving by 1.6 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -5.2%; its worst year was -28.2%.

  • Cash conversion 14 / 20

    Free cash flow was positive in 10 of 10 years, at a median 8.9% of revenue.

  • Discipline 20 / 20

    The diluted share count fell 9.0% over five years; stock-based pay has been a median 1.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (67 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $862m and EPS of $0.31 (range $0.26 to $0.34) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.49 −7% $3.6bn −3%
Next $1.48 −1% $3.6bn +1%

Next year's EPS estimate has moved −4.7% in 90 days, across 17 analysts.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.35 $0.52 +50.1%
Mar 2026 $0.27 $0.27 −1.6%
Dec 2025 $0.29 $0.27 −6.0%
Sept 2025 $0.45 $0.37 −17.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

17 analysts, Oct 2026
Buy424%
Hold1271%
Sell16%

Monthly trend

  1. Oct 2026221217
  2. Sep 2026221217
  3. Aug 2026221218
  4. Jul 202621318

Counts of recommendations published by analysts covering Dentsply Sirona Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.3%
of tradable shares
Days to cover
5.39
at average volume
Short interest, 1 month
+16%
to September 30, 2026
Held by institutions
—
of shares
Held by insiders
0.6%
of shares
Employees
14,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months −20.4%

$12.43 on October 31, 2025 to $9.90

ThenNowEffect
Revenue (last 12 months) $3.7bn $3.6bn −0.8%
P/S multiple 0.7x 0.5x −19.6%
Share count 199m 200m −0.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −63.4%

$27.04 on November 3, 2023 to $9.90

ThenNowEffect
Revenue (last 12 months) $3.9bn $3.6bn −7.4%
P/S multiple 1.5x 0.5x −63.1%
Share count 214m 200m +7.2%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
XRAY+7%−42%+14%−45%−37%−13%
Industry peers (median)+19%−50%+38%−5%−13%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
XRAY42%33%67%25%33%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
XRAY−30%−54%−35%−53%−50%−43%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 29, 2015: 86% from May 10, 2021 to October 19, 2026. Getting back needed a 637% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.42 – $14.68
From 52-week high
−32.6%
vs 50-day average
+2.3%
vs 200-day average
−12.5%
Volatility (1 year)
48%
Beta vs S&P 500
1.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±8.3%
After a week
5 up, 7 down
typical move ±8.8%
After a month
2 up, 10 down
typical move ±11.9%
Results releasedNext dayS&P 500 next day5 days21 days
May 5, 2026 −0.5% +2.2% −1.8% −11.8%
February 26, 2026 +14.7% −1.0% +4.1% −10.4%
November 6, 2025 −11.4% −1.0% −13.2% −12.0%
August 7, 2025 −5.3% +0.7% +1.4% +3.9%
July 21, 2025 +4.7% +0.2% +2.5% −10.5%
May 8, 2025 +15.6% +0.6% +20.6% +18.6%
February 27, 2025 −12.0% −0.1% −13.6% −19.8%
November 7, 2024 −25.5% +1.2% −25.5% −18.9%
October 24, 2024 −2.9% +0.2% −3.5% −21.8%
July 31, 2024 −0.2% +0.2% −11.8% −5.4%
May 2, 2024 −6.3% +2.2% −6.6% −7.1%
February 29, 2024 −0.1% +1.3% +0.4% −2.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Dentsply Sirona Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Dentsply Sirona Inc.
$3.6B $3.7B $3.8B $3.9B $4B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $3.9B Revenue (TTM), FY23 Q4: $4B Revenue (TTM), FY24 Q1: $3.9B Revenue (TTM), FY24 Q2: $3.9B Revenue (TTM), FY24 Q3: $3.9B Revenue (TTM), FY24 Q4: $3.8B Revenue (TTM), FY25 Q1: $3.7B Revenue (TTM), FY25 Q2: $3.7B Revenue (TTM), FY25 Q3: $3.6B Revenue (TTM), FY25 Q4: $3.7B Revenue (TTM), FY26 Q1: $3.7B Revenue (TTM), FY26 Q2: $3.6B $3.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $3.9B
FY23 Q4 $4B
FY24 Q1 $3.9B
FY24 Q2 $3.9B
FY24 Q3 $3.9B
FY24 Q4 $3.8B
FY25 Q1 $3.7B
FY25 Q2 $3.7B
FY25 Q3 $3.6B
FY25 Q4 $3.7B
FY26 Q1 $3.7B
FY26 Q2 $3.6B
Revenue growth, TTM YoY Dentsply Sirona Inc.
-10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -2.6% Revenue growth, TTM YoY, FY23 Q4: 1.1% Revenue growth, TTM YoY, FY24 Q1: 0.2% Revenue growth, TTM YoY, FY24 Q2: -1.0% Revenue growth, TTM YoY, FY24 Q3: -0.9% Revenue growth, TTM YoY, FY24 Q4: -4.3% Revenue growth, TTM YoY, FY25 Q1: -5.6% Revenue growth, TTM YoY, FY25 Q2: -5.8% Revenue growth, TTM YoY, FY25 Q3: -7.1% Revenue growth, TTM YoY, FY25 Q4: -3.0% Revenue growth, TTM YoY, FY26 Q1: -1.0% Revenue growth, TTM YoY, FY26 Q2: -0.8% -0.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -2.6%
FY23 Q4 1.1%
FY24 Q1 0.2%
FY24 Q2 -1.0%
FY24 Q3 -0.9%
FY24 Q4 -4.3%
FY25 Q1 -5.6%
FY25 Q2 -5.8%
FY25 Q3 -7.1%
FY25 Q4 -3.0%
FY26 Q1 -1.0%
FY26 Q2 -0.8%
Operating margin (TTM) Dentsply Sirona Inc.
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -2.4% Operating margin (TTM), FY23 Q4: -2.1% Operating margin (TTM), FY24 Q1: -1.0% Operating margin (TTM), FY24 Q2: -1.8% Operating margin (TTM), FY24 Q3: -7.6% Operating margin (TTM), FY24 Q4: -23.2% Operating margin (TTM), FY25 Q1: -23.1% Operating margin (TTM), FY25 Q2: -28.2% Operating margin (TTM), FY25 Q3: -21.9% Operating margin (TTM), FY25 Q4: -11.5% Operating margin (TTM), FY26 Q1: -14.1% Operating margin (TTM), FY26 Q2: -8.5% -8.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -2.4%
FY23 Q4 -2.1%
FY24 Q1 -1.0%
FY24 Q2 -1.8%
FY24 Q3 -7.6%
FY24 Q4 -23.2%
FY25 Q1 -23.1%
FY25 Q2 -28.2%
FY25 Q3 -21.9%
FY25 Q4 -11.5%
FY26 Q1 -14.1%
FY26 Q2 -8.5%
FCF margin (TTM) Dentsply Sirona Inc.
0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 5.5% FCF margin (TTM), FY23 Q4: 5.8% FCF margin (TTM), FY24 Q1: 7.1% FCF margin (TTM), FY24 Q2: 9.3% FCF margin (TTM), FY24 Q3: 9.4% FCF margin (TTM), FY24 Q4: 7.4% FCF margin (TTM), FY25 Q1: 7.5% FCF margin (TTM), FY25 Q2: 3.8% FCF margin (TTM), FY25 Q3: 2.2% FCF margin (TTM), FY25 Q4: 2.8% FCF margin (TTM), FY26 Q1: 2.8% FCF margin (TTM), FY26 Q2: 3.9% 3.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 5.5%
FY23 Q4 5.8%
FY24 Q1 7.1%
FY24 Q2 9.3%
FY24 Q3 9.4%
FY24 Q4 7.4%
FY25 Q1 7.5%
FY25 Q2 3.8%
FY25 Q3 2.2%
FY25 Q4 2.8%
FY26 Q1 2.8%
FY26 Q2 3.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 2,159 2,221 2,538 2,928 2,951 2,923 2,674 3,745 3,993 3,986 4,022 3,339 4,231 3,922 3,965 3,793 3,680 3,643
Gross profit 1,106 1,130 1,273 1,556 1,577 1,600 1,517 2,001 2,189 2,068 2,164 1,656 2,347 2,127 2,086 1,958 1,840 1,804
EBITDA 446 446 386 511 547 575 498 726 −1,246 −627 676 331 955 −609 258 −530 −70 39
Operating income 381 380 301 382 419 446 375 455 −1,562 −958 353 −3 608 −937 −85 −879 −422 −310
Net income 274 266 245 314 313 323 251 430 −1,550 −1,011 256 −73 411 −950 −132 −910 −598 −546
Diluted EPS $1.83 $1.82 $1.70 $2.18 $2.16 $2.24 $1.76 $1.94 −$6.76 −$4.51 $1.14 −$0.33 $1.87 −$4.41 −$0.62 −$4.48 −$3.00 −$2.73
Growth (year on year)
Revenue −1.5% +2.9% +14.3% +15.4% +0.8% −1.0% −8.5% +40.0% +6.6% −0.2% +0.9% −17.0% +26.7% −7.3% +1.1% −4.3% −3.0% −0.8%
EBITDA +2.1% −0.1% −13.5% +32.5% +7.0% +5.0% −13.3% +45.8% −271.5% — — −51.0% +188.5% −163.8% — −305.4% — —
Operating income +0.2% −0.3% −20.9% +27.0% +9.8% +6.3% −15.8% +21.2% −443.6% — — −100.8% — −254.1% — — — —
Net income −3.4% −3.1% −8.0% +28.5% −0.3% +3.1% −22.2% +71.1% −460.5% — — −128.5% — −331.1% — — — —
Diluted EPS −2.1% −0.5% −6.6% +28.2% −0.9% +3.7% −21.4% +10.2% −448.5% — — −128.9% — −335.8% — — — —
Margins
Gross margin 51.2% 50.9% 50.2% 53.1% 53.5% 54.7% 56.7% 53.4% 54.8% 51.9% 53.8% 49.6% 55.5% 54.2% 52.6% 51.6% 50.0% 49.5%
EBITDA margin 20.7% 20.1% 15.2% 17.5% 18.5% 19.7% 18.6% 19.4% −31.2% −15.7% 16.8% 9.9% 22.6% −15.5% 6.5% −14.0% −1.9% 1.1%
Operating margin 17.7% 17.1% 11.9% 13.0% 14.2% 15.2% 14.0% 12.1% −39.1% −24.0% 8.8% −0.1% 14.4% −23.9% −2.1% −23.2% −11.5% −8.5%
Net margin 12.7% 12.0% 9.6% 10.7% 10.6% 11.0% 9.4% 11.5% −38.8% −25.4% 6.4% −2.2% 9.7% −24.2% −3.3% −24.0% −16.3% −15.0%
Free-cash-flow margin 14.2% 15.0% 12.7% 9.5% 10.8% 15.8% 15.9% 11.7% 11.5% 8.0% 12.8% 16.8% 12.2% 9.4% 5.8% 7.4% 2.8% 3.9%
Cash flow
Cash from operations 362 377 393 370 418 560 497 563 602 500 639 649 657 517 377 461 235 319
Capital spending 56 44 71 92 100 100 72 125 144 183 123 87 142 149 149 180 131 176
Free cash flow 306 333 322 278 318 461 425 438 458 317 516 562 515 368 228 281 104 143
Stock-based pay 16 19 21 22 25 25 26 41 48 21 66 47 48 59 46 39 33 31
Free cash flow after stock pay 290 314 301 255 292 435 400 397 410 296 450 515 467 309 182 242 71 112
Balance sheet
Cash 450 540 77 80 75 152 285 384 321 310 405 438 339 365 334 272 326 239
Total debt 469 612 1,767 1,521 1,476 1,263 1,154 1,532 1,642 1,657 1,438 2,284 2,095 1,944 2,118 2,135 2,328 2,224
Net debt (negative = net cash) 19 72 1,690 1,441 1,401 1,111 869 1,148 1,321 1,348 1,033 1,846 1,756 1,579 1,784 1,863 2,002 1,985
Diluted shares 150m 146m 144m 144m 145m 144m 143m 222m 229m 224m 224m 219m 220m 216m 212m 203m 199m 200m
Returned to shareholders
Dividends 30 29 29 31 35 37 40 65 78 79 81 88 92 104 116 126 128 96
Buybacks 79 224 80 39 118 163 113 814 401 250 260 140 200 150 300 250 0 —
Total returned 109 253 108 70 153 201 153 879 480 329 341 228 292 254 416 376 128 96

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $5.2bn
Short-term assets $1.9bnLonger-term assets $3.3bn
What it owes, and who funded it · $5.2bn
Short-term liabilities $1.2bnLonger-term liabilities $2.7bnShareholders' equity $1.4bn
  • Short-term assets cover short-term liabilities $1.9bn of assets due within a year against $1.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.9bn short-term assets against $2.7bn of longer-dated liabilities.
  • More cash than debt $239m of cash against $2.2bn of debt.
  • Debt below 40% of shareholders' equity Debt is 165% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 38% to 165% over five years.
  • A year's operating cash flow covers at least 20% of debt $319m of operating cash flow against $2.2bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$310m against $91m of interest.

From Dentsply Sirona Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Dividends (TTM)
$96M
Buybacks, last 3 fiscal years
$550M
Diluted share count
+0.1%
year over year
Total shareholder yield
4.9%
dividends 4.9% + buybacks 0.0% of market value
R&D spending
4.6%
of revenue
Sales & admin spending
39.9%
of revenue

Competitors: side by side with peers

Closest by revenue in health care supplies
Last 12 months unless stated XRAY WST ALGN COO NVST ICUI Median
Revenue, last 12 months $3.6bn $3.4bn $4.1bn $4.2bn $2.9bn $2.2bn $1.0bn
Revenue growth, last 12 months −0.8% 12.6% 4.4% 4.7% 11.9% −9.0% 3.4%
Revenue growth, 3-year average −2.5% 5.1% 3.5% 6.4% 3.4% −2.0% 0.0%
Revenue growth, latest quarter −4.1% 8.7% 4.3% 0.6% 7.1% 0.5% 0.6%
Gross margin 49.5% 37.6% 68.0% 65.9% 55.2% 39.1% 52.9%
Operating margin −8.5% 23.0% 13.2% 12.8% 9.6% 3.3% 3.3%
Operating margin, 3-year average −12.9% 20.8% 14.9% 16.0% −10.9% 2.2% 2.2%
Net margin −15.0% 18.8% 10.0% 13.5% 3.3% 1.4% 1.4%
Cash from operations / revenue 8.8% 19.3% 18.3% 24.4% 10.6% 10.9% 10.6%
Free-cash-flow margin 3.9% 13.3% 15.3% 16.0% 8.7% 6.7% 6.7%
Free-cash-flow margin, 3-year average 5.7% 12.4% 13.8% 10.4% 10.0% 5.2% 9.8%
Stock pay / revenue 0.9% 0.8% 4.3% 1.6% 1.4% 2.5% 2.5%
Change in share count 0.1% −1.5% −2.8% −2.4% −3.3% 2.5% −0.4%

Median of all 13 companies we cover in health care supplies. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care supplies companies
Measure Company Peer median Rank
Revenue growth Growth -0.8% 3.4% 8 of 13
Change in growth rate Growth +0.3pp -0.3pp 5 of 13
Gross margin Profitability 49.5% 52.9% 8 of 13
Operating margin Profitability -8.5% 3.3% 10 of 13
Net margin Profitability -15.0% 1.4% 9 of 13
Free-cash-flow margin Cash generation 3.9% 6.7% 9 of 13
Stock pay as % of revenue Cash generation 0.9% 2.5% 2 of 13
Long-term debt as % of assets Balance sheet 38.4% 15.4% 8 of 9
Change in share count Balance sheet 0.1% 0.1% 7 of 12

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue YoY
Other Foreign $2.1B ▲ 2.0%
Europe $1.6B ▲ 3.8%
United States $1.2B ▼ 12.3%
Rest of The World $922M ▼ 0.5%
Germany $422M ▲ 2.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Dentsply Sirona Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.4B
Institutions reporting
370
Shares held vs prior quarter
▲ 6.5%
Positions opened / closed
57 / 64

Top buyers and sellers, Q2 2026: 200 institutions bought and 179 sold ; the biggest buyer was Blackrock, Inc (+7.5M shares) and the biggest seller First Eagle Investment Management, LLC (−13.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $283M 26.7M 11.8% ▲ 38.7%
Fuller & Thaler Asset Management, Inc. $135M 12.7M 5.6% ▼ 0.7%
Vanguard Portfolio Management LLC $125M 11.8M 5.2% ▲ 11.9%
AQR Capital Management LLC $110M 10.5M 4.6% ▲ 163.8%
State Street Corp $98.5M 9.3M 4.1% ▲ 28.2%
Vanguard Capital Management LLC $96M 9.0M 4.0% ▲ 0.5%
Lazard Asset Management LLC $87.7M 8.3M 3.6% ▲ 23.1%
Ariel Investments, LLC $85.2M 8.0M 3.5% ▲ 25.7%
Southpoint Capital Advisors LP $74.3M 7.0M 3.1% ▼ 30.0%
Cooke & Bieler LP $73.5M 6.9M 3.1% ▼ 11.2%
Geode Capital Management, LLC $60M 5.7M 2.5% ▲ 47.8%
Invenomic Capital Management LP $52.1M 4.9M 2.2% ▲ 11.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Dentsply Sirona Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1.7M 12 trades by 9 insiders, last 12 months Insider sales History → $915,708 1 trade by 1 insider · 0% under pre-set plans
Net ▲ $825,669 net buying
Insider Date Trade Shares Price Value
Gladden Brian T Director June 15, 2026 Buy 9,985 $10.02 $100,050
Hosein Clyde Director June 15, 2026 Buy 6,500 $9.99 $64,935
Mckeon Brian P Director June 12, 2026 Buy 10,000 $10.12 $101,200
Mazelsky Jonathan Jay Director June 12, 2026 Buy 10,000 $10.14 $101,400
Barber Michael J Director June 11, 2026 Buy 15,175 $9.89 $150,081
Holden Betsy D Director June 11, 2026 Buy 10,086 $9.88 $99,650
Forbes James D Director March 9, 2026 Buy 5,000 $12.48 $62,400
Lucier Gregory T Director March 9, 2026 Buy 15,000 $12.45 $186,750
Forbes James D Director March 3, 2026 Buy 5,000 $13.47 $67,350
Lucier Gregory T Director March 3, 2026 Buy 22,445 $14.03 $314,903
Lucier Gregory T Director March 2, 2026 Buy 27,555 $14.25 $392,659
Lucier Gregory T Director December 8, 2025 Sell 82,200 $11.14 $915,708

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 12 trades and filings

No trades in Dentsply Sirona Inc. disclosed in the last 12 months; 12 earlier trades on record.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded January 8, 2025, filed February 11, 2025
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (partial), $1,001 - $15,000, traded January 7, 2025, filed February 11, 2025
  • Lois Frankel(D-FL 21):Sale (full), $1,001 - $15,000, traded December 5, 2021, filed January 16, 2022

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around August 6, 2026 estimated from the company's past filing pattern, not announced

  • May 5, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025
  • July 21, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Dentsply Sirona Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Dentsply Sirona Inc. in brief

What does Dentsply Sirona Inc. do?
Dentsply Sirona Inc. is a US-listed company in the health care supplies industry. Its financial year ends in December.
What is Dentsply Sirona Inc.'s stock ticker?
Dentsply Sirona Inc. trades under the ticker XRAY on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Dentsply Sirona Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Dentsply Sirona Inc. reported revenue of $3.6B, 0.8% lower than a year earlier, according to its SEC filings.
What is Dentsply Sirona Inc.'s free cash flow?
Dentsply Sirona Inc.'s free-cash-flow margin is 3.9% of revenue over the trailing twelve months, ranking 9 of the 13 health care supplies companies we cover.
Who are Dentsply Sirona Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Fuller & Thaler Asset Management, Inc. and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Dentsply Sirona Inc.'s market cap?
On November 2, 2026, Dentsply Sirona Inc.'s market capitalisation was about $2B and net debt of $2B. Market figures come from third-party market data and may be delayed.
Does Dentsply Sirona Inc. pay a dividend?
Yes: Dentsply Sirona Inc. paid $96M in dividends over the trailing twelve months, a dividend yield of 4.87%.
How much debt does Dentsply Sirona Inc. have?
Dentsply Sirona Inc.'s debt-to-equity ratio is 164.6%, from its latest balance sheet (38.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Dentsply Sirona Inc.'s competitors?
In our Health Care Supplies peer group, the companies closest to Dentsply Sirona Inc. are West Pharmaceutical Services, Align Technology, The Cooper Companies, Envista Holdings Corp and ICU Medical Inc. The side-by-side comparison below sets their revenue, margins and growth against Dentsply Sirona Inc.'s.
Are insiders buying or selling Dentsply Sirona Inc. stock?
Over the last 12 months, Dentsply Sirona Inc.'s directors and officers reported 12 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Dentsply Sirona Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Dentsply Sirona Inc. announces its own schedule.